Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database

Objective To develop, validate, and evaluate a new QRISK model to estimate lifetime risk of cardiovascular disease. Design Prospective cohort study with routinely collected data from general practice. Cox proportional hazards models in the derivation cohort to derive risk equations accounting for competing risks. Measures of calibration and discrimination in the validation cohort. Setting 563 general practices in England and Wales contributing to the QResearch database. Subjects Patients aged 30–84 years who were free of cardiovascular disease and not taking statins between 1 January 1994 and 30 April 2010: 2 343 759 in the derivation dataset, and 1 267 159 in the validation dataset. Main outcomes measures Individualised estimate of lifetime risk of cardiovascular disease accounting for smoking status, ethnic group, systolic blood pressure, ratio of total cholesterol:high density lipoprotein cholesterol, body mass index, family history of coronary heart disease in first degree relative aged <60 years, Townsend deprivation score, treated hypertension, rheumatoid arthritis, chronic renal disease, type 2 diabetes, and atrial fibrillation. Age-sex centile values for lifetime cardiovascular risk compared with 10 year risk estimated using QRISK2 (2010). Results Across all the 1 267 159 patients in the validation dataset, the 50th, 75th, 90th, and 95th centile values for lifetime risk were 31%, 39%, 50%, and 57% respectively. Of the 10% of patients in the validation cohort classified at highest risk with either the lifetime risk model or the 10 year risk model, only 18 385(14.5%) were at high risk on both measures. Patients identified as high risk with the lifetime risk approach were more likely to be younger, male, from ethnic minority groups, and have a positive family history of premature coronary heart disease than those identified with the 10 year QRISK2 score. The lifetime risk calculator is available at www.qrisk.org/lifetime/. Conclusions Compared with using a 10 year QRISK2 score, a lifetime risk score will tend to identify patients for intervention at a younger age. Although lifestyle interventions at an earlier age could be advantageous, there would be small gains under the age of 65, and medical interventions carry risks as soon as they are initiated. Research is needed to examine closely the cost effectiveness and acceptability of such an approach.

[1]  T. Dent,et al.  Predicting the risk of coronary heart disease. II: the role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction. , 2010, Atherosclerosis.

[2]  T. Dent,et al.  Predicting the risk of coronary heart disease I. The use of conventional risk markers. , 2010, Atherosclerosis.

[3]  Ralph D'Agostino,et al.  Risk Prediction in Cardiovascular Medicine Cardiovascular Risk-Estimation Systems in Primary Prevention Do They Differ ? Do They Make a Difference ? Can We See the Future ? , 2010 .

[4]  Ross J. Simpson,et al.  Improving Cardiovascular Risk Reduction for Primary Prevention—Utility of Lifetime Risk Assessment , 2010, Postgraduate medicine.

[5]  J Wouter Jukema,et al.  Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. , 2010, Archives of internal medicine.

[6]  Carol Coupland,et al.  Predicting the risk of Chronic Kidney Disease in Men and Women in England and Wales: prospective derivation and external validation of the QKidney® Scores , 2010, BMC family practice.

[7]  H. Young Putting prevention first - vascular checks: risk assessment and management , 2010 .

[8]  Carol Coupland,et al.  Individualising the risks of statins in men and women in England and Wales: population-based cohort study , 2010, Heart.

[9]  Carol Coupland,et al.  Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.

[10]  Gary S Collins,et al.  An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study , 2010, BMJ : British Medical Journal.

[11]  Rod Jackson,et al.  ‘Your Heart Forecast’: a new approach for describing and communicating cardiovascular risk? , 2010, Heart.

[12]  Donald Lloyd-Jones,et al.  Screening for cardiovascular risk in asymptomatic patients. , 2010, Journal of the American College of Cardiology.

[13]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[14]  Y. Mishriki Puzzles in Practice , 2010, Postgraduate medicine.

[15]  Carol Coupland,et al.  Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores , 2009, BMJ : British Medical Journal.

[16]  Gary S Collins,et al.  An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study , 2009, BMJ : British Medical Journal.

[17]  Ewout W. Steyerberg,et al.  Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction , 2009, Epidemiology.

[18]  Michael J. Pencina,et al.  Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[19]  Aziz Sheikh,et al.  Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore , 2009, BMJ : British Medical Journal.

[20]  A. Sheikh,et al.  Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2 , 2008, BMJ : British Medical Journal.

[21]  J. Robson,et al.  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease , 2007, Heart.

[22]  S. Allender,et al.  Coronary heart disease statistics. , 2008 .

[23]  J. Hippisley-Cox,et al.  Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study , 2007, Heart.

[24]  J. Hippisley-Cox,et al.  Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study , 2007, BMJ : British Medical Journal.

[25]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.

[26]  T Fahey,et al.  Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review , 2006, Heart.

[27]  Ralph B D'Agostino,et al.  Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age , 2006, Circulation.

[28]  P. Royston Multiple Imputation of Missing Values , 2004 .

[29]  Ralph B D'Agostino,et al.  Framingham risk score and prediction of lifetime risk for coronary heart disease. , 2004, The American journal of cardiology.

[30]  Patrick Royston,et al.  A new measure of prognostic separation in survival data , 2004, Statistics in medicine.

[31]  J. Feinglass,et al.  Favorable cardiovascular risk profile in middle age and health-related quality of life in older age. , 2003, Archives of internal medicine.

[32]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[33]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[34]  R. Bonow Primary prevention of cardiovascular disease: a call to action. , 2002, Circulation.

[35]  Alastair Gray,et al.  Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63) , 2002, BMJ : British Medical Journal.

[36]  Sudha Seshadri,et al.  Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. , 2002, JAMA.

[37]  S. Ebrahim,et al.  Multiple risk factor interventions for primary prevention of coronary heart disease. , 2000, The Cochrane database of systematic reviews.

[38]  Enrique Sanchez-Delgado,et al.  Lifetime risk of developing coronary heart disease , 1999, The Lancet.

[39]  Patrick Royston,et al.  A method for estimating age‐specific reference intervals (‘normal ranges’) based on fractional polynomials and exponential transformation , 1998 .

[40]  A. Gotto The Multiple Risk Factor Intervention Trial (MRFIT). A return to a landmark trial. , 1997, JAMA.

[41]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .